| Symbol
| ENTPD1
| contributors: mct - updated : 05-12-2016
|
| HGNC name
| ectonucleoside triphosphate diphosphohydrolase 1
|
| HGNC id
| 3363
|
| corresponding disease(s)
|
SPG64
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
| |
correlated with better long-term survival after tumor resection in patients with pancreatic cancer | | tumoral
|
|
| --over
|
|
in malignant epithelial cells of human rectal adenocarcinoma  | | constitutional
|
|
| --low
|
| |
decreased in the late-onset preeclamptic (PE) placenta | |
Variant & Polymorphism
| 
| |
| Candidate gene
| marker of a Treg subset likely involved in the control of the inflammatory autoimmune disease |
| Marker
| dysregulated levels of ENTPD1 genes may be involved in sepsis pathophysiology and may be utilized as potential diagnostic biomarker |
|
ENTPD1 may act as potential markers for the clinical diagnosis of PE |
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| dermatology | skin | | |
| biochemical or biological inhibitors of ENTPD1 and/or NT5E may hold promise in the treatment of dermal fibrosis in diseases such as scleroderma | | cancer | hemopathy | | |
| may serve as a future target for the development of novel therapies with immune-modulating antitumor agents in chronic lymphocytic leukemia | | reproduction | pregnancy | placenta | |
| CD39 is a target for the clinical treatment of PE |
| |
|
| Entpd1 null mice exhibit decreased synaptic efficacy, presumably due to desensitization P2X1 receptors | |
in rat models of DNA damage, inhibiting Entpd1-driven ATP hydrolysis with POM-1 protected the heart and lung tissues against chemically induced DNA damage |